购物车
- 全部删除
- 您的购物车当前为空
Rg3039 (PF-06687859) 是一种具有口服活性、能够透过血脑屏障的DcpS 抑制剂,其IC50=0.069 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
Rg3039 (PF-06687859) 是一种具有口服活性、能够透过血脑屏障的DcpS 抑制剂,其IC50=0.069 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 297 | 现货 | |
5 mg | ¥ 496 | 现货 | |
10 mg | ¥ 792 | 现货 | |
25 mg | ¥ 1,590 | 现货 | |
50 mg | ¥ 2,430 | 现货 | |
100 mg | ¥ 3,580 | 现货 | |
500 mg | ¥ 7,780 | 现货 |
产品描述 | Rg3039 (PF-06687859) is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy. Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. RG3039 improves motor function in SMA mice. RG3039 also showed activity to improve survival, function and motor unit pathologies in two SMA mouse models. |
靶点活性 | DcpS:0.069 nM. |
别名 | PF-06687859 |
分子量 | 432.35 |
分子式 | C21H23Cl2N5O |
CAS No. | 1005504-62-0 |
Smiles | Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1 |
密度 | 1.375 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||
溶解度信息 | H2O: < 0.1 mg/mL (insoluble) DMSO: 1 mg/mL (2.31 mM), Sonication is recommended. ![]() | ||||||||||
溶液配制表 | |||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容